江苏欧歌

Jiangsu Ouge is a clinical-stage biopharmaceutical company based in Suzhou, China, dedicated to the discovery and development of innovative peptide therapeutics for metabolic diseases. The company focuses on multi-target agonists, particularly those targeting the GLP-1, GIP, and Glucagon receptors, to address the growing global burden of obesity, type 2 diabetes, and NASH. Its lead candidate, OG-411, is a long-acting dual GLP-1/GIP receptor agonist currently in Phase 2 clinical trials for weight management and glycemic control. By leveraging advanced peptide engineering and optimization technologies, Jiangsu Ouge aims to develop next-generation metabolic treatments with superior efficacy and safety profiles. The company is strategically located in the Suzhou Biobay industrial cluster, benefiting from a robust ecosystem for biotechnology innovation.